



**Effectual
Services**

Intelligence That Matters

Monthly
Newsletter
from
Effectual
Services

Dear Readers,

Welcome to **NewsEffect** –
July 2022

Newsletter Contents


- Polycarbonate Material in EV
- Disruptive Technology Leads
- IP News

Polycarbonate Material in EV




- SABIC, a global leader in the chemical industry, has introduced [NORYL NHP8000VT3 resin](#), a product well-suited for insulation film used in electric vehicle (EV) battery modules to help improve protection against short circuits and fire propagation. The high-performance, polyphenylene ether (PPO)-based resin is engineered with patented technologies to help meet the stringent demands of higher-voltage batteries (600-800 volts). It achieves the highest comparative tracking index performance level category (CTI PLC0); provides ultra-thin-wall extrusion and thermoforming capability; and meets the UL94 V0 standard at 0.25 mm with non-brominated, non-chlorinated flame retardance.
- A student team from the Eindhoven University of Technology has managed to develop a prototype electric passenger car that removes and stores carbon dioxide from the air as it rolls down the road. Designed with the aim of capturing more CO₂ than is emitted during the full lifecycle of the vehicle, this vehicle would significantly improve the lifetime carbon footprint of producing and running EVs over their lifetimes. The team chose [polycarbonate](#) over glass for the windows since it is deemed to be more environmentally friendly.
- Samyang Corporation sets out to achieve both eco-friendliness and high performance by developing an additive-free transparent [flame-retarding polycarbonate](#). Polycarbonate is a transparent, impact- and heat-resistant engineering plastic material often used for the interior and exterior finishes of vehicles, electronic appliances, soundproof walls, and medical device components.
- The global Automotive [Polycarbonate](#) Glazing Sales market size is projected to reach USD 1266.7 million by 2026, from USD 909.8 million, at a CAGR of 5.7% during 2022-2026. Pre & Post COVID-19 Impact Covered in this Report. Automotive Polycarbonate Glazing Market Size 2022-2026 presents detailed competitive analysis including the market Share, Size, Future scope. This study categorize breakdown data by manufacturers, region, type and applications, also analyzes the market drivers, opportunities and challenges.
- Polymers have been increasingly important in the automotive sector in recent years. Polymers are the most crucial resources for building a high-performance, compact, fuel-efficient, reliable, and cost-effective automobile. Automotive cockpits could be provided with big touchscreens and smart surfaces displaying graphics thanks to transparent materials like [polycarbonate](#), a potential contender for substituting glass in windows and windscreens. Another increasing trend in electric vehicles is battery pack simplicity, which will allow EVs to compete with vehicles powered by internal combustion engines.
- Transparency Market Research delivers key insights on the [global polycarbonate market](#). In terms of revenue, the global polycarbonate market is estimated to expand at a CAGR of 6.2% during the forecast period, owing to numerous factors, regarding which TMR offers thorough insights and forecast in its report on the global polycarbonate market. The global polycarbonate market is broadly affected by several factors, including increase in usage of polycarbonate in various applications of automotive, electronics, construction, optical media, and packaging sectors.

Disruptive Technology Leads



- SMIC (Semiconductor Manufacturing International Corporation), a [Shanghai based semiconductor company has unveiled its home grown 7 nanometer chip manufacturing process](#). The process is currently being used to manufacture Bitcoin-mining semiconductors for China based MinerVa Semiconductor Corp.



- A [new CRISPR-based therapy](#) to decrease cholesterol is undergoing preliminary testing in New Zealand in **July 2022**. The one-and-done treatment could save countless lives by permanently decreasing cholesterol and the risk of a heart attack if it performs as well as it did in animal studies. It is intended to permanently inactivate a gene in the liver that regulates the development of PCSK9, a protein that hinders the body's ability to eliminate extra cholesterol.

- [Chinese networking equipment manufacturer H3C announced the world's first Wi-Fi 7 router](#), the Magic BE18000. The BE18000 is backwards compatible with the previous Wi-Fi generation. BE18000 supports speeds up to 1148 Mbps on 2.4Ghz, 5765 Mbps on 5Ghz, and 11530 Mbps on 6Ghz frequencies. BE18000 offers Multi-link operation which allows devices to use multiple frequency bands at once to reduce latency. The pricing and availability hasn't been announce by the H3C. This could be due to the fact that most countries haven't yet delicensed the 6Ghz frequency band. It is worth noting that the specification for Wi-Fi 7 (802.11be) hasn't been finalized by IEEE yet which could mean that router may not support all the features of the Wi-Fi 7.



- Engineers have discovered on **July 3, 2022** a [method for producing sustainable concrete](#) that involves mixing in live organisms. The substance can trap carbon and store it within the concrete, making the process not just carbon neutral but possibly even carbon negative. Microalgae with one cell are known as coccolithophores. These minuscule organisms are covered in microscopic calcium carbonate plates, which are the same mineral that makes up the bones and shells of several aquatic species. Another essential component of limestone is calcium carbonate. Coccolithophores were employed by the University of Colorado Boulder team who developed the novel cement-making technique to generate calcium carbonate and transform it into a limestone substitute that can be used to make concrete.



- Obsidian Therapeutics, Inc.'s lead engineered tumor infiltrating lymphocyte (TIL) therapy candidate, [OBX-115, was approved by the Food and Drug Administration \(FDA\)](#) for an MD Anderson-sponsored Phase I clinical study. The announcement was made on **July 21, 2022** by the University of Texas MD Anderson Cancer Center and Obsidian Therapeutics, Inc. As part of a deal announced in 2020, OBX-115 has been developed in cooperation with MD Anderson. In the upcoming first-in-human single-arm, open-label Phase I research, adult patients with metastatic melanoma who have relapsed or become resistant to earlier treatment regimens comprising anti-PD-1 antibodies will be assessed for safety and preliminary efficacy of OBX-115 as monotherapy.

IP News



- [A German court has given the decision in favor of smartphone brand Nokia](#) in its 4G/5G patent dispute against OPPO. Nokia had sued OPPO over nine Standard Essential Patents (SEPs) and five implementation patents in three regional German Courts.

- Due to BioNTech's usage of mRNA technology in Germany, biotech business [CureVac has filed a patent case against the company](#). According to an announcement, the corporation is suing BioNTech and two of its subsidiaries for violating its intellectual property rights and is asking for "appropriate recompense. The development of mRNA technology over the course of more than two decades, some of which were employed by BioNTech and Pfizer for the creation and marketing of their Comirnaty coronavirus vaccine, was the basis for CureVac's claim to intellectual property rights, the company claims.

- [Apple has filed several new patents](#) in software and hardware related to riding comfort such as seats and suspension to develop a self driving car. The iPhone makers is also working on vehicle-to-everything (V2X) technology.

- [BioNTech and Pfizer assert that they did not violate CureVac's patents](#), BioNTech and Pfizer petitioned a federal court in Massachusetts to rule that they had not violated CureVac patents relating to the COVID-19 vaccine technology. The drug maker said CureVac was threatening them with a "groundless patent infringement complaint. The businesses sued CureVac because they claimed it "had been unable to put to market any product to help in the fight against COVID-19." According to their complaint, CureVac is currently attempting to capitalise on the popularity of the BioNTech and Pfizer vaccine by threatening to violate patents.

- [The Secretary of the Department of Health and Human Services, the U.S. Food and Drug Administration, and its Commissioner were all named in a lawsuit brought by Avadel Pharmaceuticals.](#)

By failing to approve its narcolepsy medicine, Lumryz, the agencies allegedly committed a mistake under the Administrative Procedure Act and broke the Food, Drug, and Cosmetics Act. The FDA tentatively approved Lumryz, according to a July 19 announcement from Dublin, Ireland-based Avadel Pharma. "Tentative approval" means that Lumryz has complied with all necessary requirements for quality, safety, and efficacy in order to receive approval in the United States, according to the business. The FDA's Orange Book lists U.S. Patent No. 8,731,963 as the "REMS patent," which is still seeking resolution. The drug is a once-at-bedtime formulation of sodium oxybate for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy.

- [Biogen revealed that it is paying \\$900 million to settle a lawsuit in addition to discontinuing a Phase II schizophrenia programme](#)

and praising the promise of lecanemab, its next attempt at treating Alzheimer's disease. Former employee Michael Bawduniak filed the whistleblower action, alleging that the business had bribed doctors to prescribe its multiple sclerosis medications over those of its rivals. It was planned for the trial in this case to start on July 26. The settlement, which Biogen secretly announced in its quarterly earnings release, is still awaiting U.S. Justice Department approval. This payment will be the highest ever reached by a whistleblower under the False Claims Act without the involvement or collaboration of the government, according to Thomas M. Greene, Bawduniak's main attorney.

USA

Suite-427,425 Broadhollow Road, Melville | NY-11747
+1-972-256-8133

INDIA

SDF A-05, NSEZ, Noida–Dadri Road, Noida Phase II -201305
Unit No: 402, 4th Floor, Tower-A, Bestech Business Tower,
Sector-66 Mohali, Punjab – 160066, India
+91-120-4522210

SINGAPORE

531A, Upper Cross Street, Singapore- 051531
+91-120-4522211

info@effectualservices.com

The sum of
human
ingenuity and
expertise that
powers us.



Human interactions
that drive
innovation.

EffectUal
Services

Intelligence That Matters



SAN FRANCISCO & NEW YORK (U.S.A) | LONDON & STUTTGART (EUROPE) | NOIDA & MOHALI (INDIA) | SINGAPORE

We are a global research & consulting firm, with a specialization in Intellectual Property (IP) Management, enabling Fortune 500's, law firms, patent owners, inventors, research institutes, universities & venture capital / PE firms, to protect their IP, discover its inherent value and generate revenue